Why is Corona Remedies Ltd falling/rising?

As of 19-Jun, Corona Remedies Ltd's stock price is rising, currently at Rs 1,863.50, reflecting a change of Rs 30.85 or 1.68% increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 7.82% compared to the Sensex's 1.69%. Additionally, the stock has shown a strong performance over the last four days, with a cumulative return of 7.88%.Today's trading activity indicates a positive trend, as the stock reached an intraday high of Rs 1,881.85, marking a 2.68% increase. Furthermore, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is often seen as a bullish signal. There has also been a significant increase in investor participation, with delivery volume on June 18 rising by 486.47% compared to the 5-day average, indicating heightened interest from investors.Institutional investors have also increased their stake in the company by 0.66% over the previous quarter, now holding 9.26% of the company. This suggests growing confidence in the company's fundamentals, as institutional investors typically have more resources to analyze the market. Overall, these factors contribute to the rising stock price of Corona Remedies Ltd.

Which are the latest news on Corona Remedies?

Corona Remedies Ltd Gains 7.82%: 5 Key Factors Driving the Week’s Momentum Corona Remedies Ltd Upgraded to Hold by MarketsMOJO on Strengthened Fundamentals and Technicals

Should I buy, sell or hold Corona Remedies Ltd?

Based on the current analysis of Corona Remedies Ltd, it would be advisable to hold your position in the company. The company demonstrates strong long-term fundamental strength, despite a current average Return on Capital Employed (ROCE) of 0%. While the operating profit has not shown growth, the fact that the company is net-debt free is a positive indicator of its financial health.Additionally, there has been an increase in institutional investor participation, with a 0.66% rise in their stake over the previous quarter, bringing their total ownership to 9.26%. This suggests a growing confidence among more sophisticated investors who typically have better resources to assess the company's fundamentals.However, it's worth noting that the company reported a decline in profit before tax for the latest quarter, which fell by 15.8% compared to the previous four-quarter average. The valuation appears high with a 13.3 enterprise value to capital employed, and while profits have increased by 34% over the past year, the flat results indicate some caution.Overall, holding your investment seems prudent given the company's solid long-term fundamentals and the increasing interest from institutional investors, despite the recent performance challenges.

What does Corona Remedies do?

Overview:Corona Remedies Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.History:The specific incorporation year and any status changes are not provided. The latest quarterly results reported are for March 2026, showing net sales and profit figures.Financial Snapshot:Net Sales: 353 Cr (Quarterly Results - Mar 2026) Net Profit: 45 Cr (Quarterly Results - Mar 2026) Market-cap: INR 10,856 Cr (Small Cap)Key Metrics:P/E: 53.00 Industry P/E: 34 Dividend Yield: 0.00% Debt Equity: 0.16 Return on Equity: 26.75% Price to Book: 14.50 Contact Details:Registrar Address: Not available. Phone: Not available. Email: Not available. Website: Not available.

How big is Corona Remedies?

As of 10th June, Market Cap: Corona Remedies Ltd has a market capitalization of 10,856.00 Cr, categorizing it as a Small Cap company.Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,403.18 Cr, while the sum of Net Profit for the same period is 185.12 Cr.Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 606.34 Cr, and Total Assets amount to 929.86 Cr.

CORONA Share Price | Corona Remedies Ltd Stock Analysis & Recommendation

Key Events This Week

15 Jun: Technical momentum shifts signal mild bullish outlook

16 Jun: Momentum shifts amid sideways trend

17 Jun: New 52-week high at Rs.2,097.35 and upper circuit hit

19 Jun: Quality grade upgraded to Excellent and Mojo rating raised to Hold

Read full news article

Corona Remedies Ltd Upgraded to Hold by MarketsMOJO on Strengthened Fundamentals and Technicals

Corona Remedies Ltd has seen its investment rating upgraded from Sell to Hold, reflecting significant improvements in its quality metrics and technical outlook. The pharmaceutical company’s enhanced fundamentals, coupled with a shift to a mildly bullish technical trend, have prompted analysts to revise their stance, signalling cautious optimism for investors amid a challenging sector backdrop.

Read full news article

Corona Remedies Ltd Upgrades Quality Grade to Excellent Amid Strong Financial Metrics

Corona Remedies Ltd has seen a significant upgrade in its quality grading from good to excellent, reflecting marked improvements in its core business fundamentals. The pharmaceutical company’s enhanced return ratios, robust debt management, and consistent operational performance have contributed to this positive reassessment, positioning it favourably within the Pharmaceuticals & Biotechnology sector.

Read full news article

[ { "link": "quarterly", "btn_text": "All Quarterly Results", "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ", "rhs": [ { "prefix": "Net Sales ", "suffix": "QoQ Growth in quarter ended Mar 2026 is 3.12% vs -5.18% in Dec 2025", "dir": 1 }, { "prefix": "Standalone Net Profit ", "suffix": "QoQ Growth in quarter ended Mar 2026 is 9.21% vs -20.90% in Dec 2025", "dir": 1 } ], "table": { "header": [ "Mar'26", "Dec'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "353.09", "val2": "342.42", "chgp": "3.12%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "62.02", "val2": "83.16", "chgp": "-25.42%", "chgp_class": "negative" }, { "field": "Interest", "val1": "1.38", "val2": "1.66", "chgp": "-16.87%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "-19.10", "chgp": "100.00%", "chgp_class": "positive" }, { "field": "Standalone Net Profit", "val1": "45.05", "val2": "41.25", "chgp": "9.21%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "17.56%", "val2": "24.29%", "chgp": "-6.73%", "chgp_class": "negative" } ] } }, { "link": "half-yearly", "btn_text": "All Half Yearly Results", "header": "Half Yearly Results Snapshot (Standalone) - Sep'25", "rhs": [ { "prefix": "Net Sales ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 }, { "prefix": "Standalone Net Profit ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 } ], "table": { "header": [ "Sep'25", "Sep'24", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "707.67", "val2": "605.04", "chgp": "16.96%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "148.25", "val2": "116.34", "chgp": "27.43%", "chgp_class": "positive" }, { "field": "Interest", "val1": "3.92", "val2": "6.02", "chgp": "-34.88%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "0.00", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "98.55", "val2": "72.93", "chgp": "35.13%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "20.95%", "val2": "19.23%", "chgp": "1.72%", "chgp_class": "positive" } ] } }, { "link": "nine-monthly", "btn_text": "All Nine Monthly Results", "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25", "rhs": [ { "prefix": "Net Sales ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 }, { "prefix": "Standalone Net Profit ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 } ], "table": { "header": [ "Dec'25", "Dec'24", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "1,050.09", "val2": "902.73", "chgp": "16.32%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "231.41", "val2": "185.76", "chgp": "24.57%", "chgp_class": "positive" }, { "field": "Interest", "val1": "5.58", "val2": "8.41", "chgp": "-33.65%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "-19.10", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "139.80", "val2": "117.70", "chgp": "18.78%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "22.04%", "val2": "20.58%", "chgp": "1.46%", "chgp_class": "positive" } ] } }, { "link": "annual", "btn_text": "All Annual Results", "header": "Annual Results Snapshot (Standalone) - Mar'26", "rhs": [ { "prefix": "Net Sales ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 }, { "prefix": "Standalone Net Profit ", "suffix": "Not Applicable: The company has declared_date for only one period", "dir": 0 } ], "table": { "header": [ "Mar'26", "Mar'25", "Change(%)" ], "body": [ { "field": "Net Sales", "val1": "1,403.18", "val2": "1,196.42", "chgp": "17.28%", "chgp_class": "positive" }, { "field": "Operating Profit (PBDIT) excl Other Income", "val1": "293.44", "val2": "239.98", "chgp": "22.28%", "chgp_class": "positive" }, { "field": "Interest", "val1": "6.97", "val2": "10.60", "chgp": "-34.25%", "chgp_class": "positive" }, { "field": "Exceptional Items", "val1": "-19.10", "val2": "0.00", "chgp": "", "chgp_class": "neutral" }, { "field": "Standalone Net Profit", "val1": "184.85", "val2": "149.05", "chgp": "24.02%", "chgp_class": "positive" }, { "field": "Operating Profit Margin (Excl OI)", "val1": "20.91%", "val2": "20.06%", "chgp": "0.85%", "chgp_class": "positive" } ] } } ]